Alkermes (ALKS) Amortization of Deferred Charges (2012)
Alkermes' (ALKS) quarterly Amortization of Deferred Charges came in at $2.0 million in Q3 2012.
Powered by 
Analysis
Alkermes (ALKS) Amortization of Deferred Charges (2012) Analysis & Trends
Alkermes (ALKS) has reported Amortization of Deferred Charges for 1 consecutive years, with $2.0 million the latest figure, recorded in Q3 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.93 Bn | 625.17 Bn | 17.26 Bn |
| 2 | AbbVie | 443.06 Bn | 436.49 Bn | 12.70 Bn |
| 3 | Merck | 365.76 Bn | 358.62 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.47 Bn | 258.78 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.36 Bn | 44.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn |